Effect of Etoposide loaded Nanoparticles in the Treatment of Advanced Liver Diseases

Abstract

Advanced liver diseases (ALD) continue to pose significant health challenges due to their high global prevalence and limited currently available curative options, besides liver transplantation. Liver disease therapeutics include many substances that may have insufficient effectiveness and severe adverse effects, such as Etoposide, having toxic nature with low compatibility and solubility in an aqueous solution. Nanoparticle-based therapeutics emerged as an efficient and safe treatment option to minimize side effects. Etoposide used for ALD is more toxic with low biocompatibility and solubility in an aqueous solution which makes it less efficient. The purpose of the study is to use nanoparticle-based etoposide for the treatment of ALD by improving its biocompatibility and solubility which makes this target-based therapy less toxic and more effective. Rat models used in this study were introduced with CCL4 and Urethane co-administration to develop liver cirrhosis. The thin film hydration method was used to synthesize etoposide-encapsulated liposomal nanoparticles. The stability and stealth effect of liposomes were enhanced by polyethylene glycol (PEG) coating. Etoposides and PEG-coated etoposide liposomes were administered intravenously, into diseased rats. Results showed that etoposide and PEG-coated liposomal encapsulation are highly effective as compared to etoposide alone and blank nanoparticles and hence, be a substantial strategy for the treatment of ALD through intravenous drug delivery system.